Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
News Archive
December 2021
-
Media ReleaseDec 09, 2021Novartis announces positive results from year two of the Phase III trial of Beovu® in diabetic macular edemaResults from year two of the Phase III KESTREL clinical trial confirmed year one findings, with an overall favorable benefit-risk profile for Beovu® (brolucizumab) 6 mg in patients with visual…
-
Media ReleaseDec 08, 2021New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancerData from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2-…
-
StoryDec 06, 2021From Our Labs
When it comes to cancer, there’s power in a good partner -
Media ReleaseDec 06, 2021Bilateral transaction between Novartis and Roche successfully closedBasel, December 6, 2021 — The bilateral transaction between Novartis and Roche for the sale of 53.3 million (approximately 33%) Roche bearer shares has successfully closed today, December 6, 2021.…
-
Media ReleaseDec 02, 2021Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platformsFocused medicines company delivering strong operational performanceBuilding depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint Confident to…
November 2021
-
Featured NewsNov 29, 2021Novartis at ASH
-
StoryNov 18, 2021Discovery
The art of drug design in a technological age -
StoryNov 12, 2021Discovery
Stopping this coronavirus – and the next one -
Media ReleaseNov 08, 2021Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021Treatment with Cosentyx® (secukinumab) resulted in a 72% reduced flare risk versus placebo, with improvement in disease activity over two years across both enthesitis-related arthritis (ERA) and…
-
Media ReleaseNov 08, 2021Novartis announces new publication in Cephalalgia of data showcasing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine preventionHER-MES, a Phase IV study, is the first and only randomized, double blind, head-to-head study that compares an antibody targeting the CGRP pathway, Aimovig® (erenumab), with an oral prophylactic…
-
Media ReleaseNov 08, 2021Leqvio®* (inclisiran) reduced LDL-C in people who are overweight or obeseRegardless of body mass index (BMI), Leqvio provided sustained and effective LDL-C reduction of ~50% with two doses a year**, according to pooled analysis of three Phase III studies 1Being overweight…
-
StoryNov 08, 2021Discovery
Solving the puzzle of immunotherapy